Clinical Trials Browser

Interventional × Cholangiocarcinoma × sacituzumab govitecan × Clear all

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor